CY1125400T1 - Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων - Google Patents
Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτωνInfo
- Publication number
- CY1125400T1 CY1125400T1 CY20221100511T CY221100511T CY1125400T1 CY 1125400 T1 CY1125400 T1 CY 1125400T1 CY 20221100511 T CY20221100511 T CY 20221100511T CY 221100511 T CY221100511 T CY 221100511T CY 1125400 T1 CY1125400 T1 CY 1125400T1
- Authority
- CY
- Cyprus
- Prior art keywords
- novel anti
- human gpvi
- gpvi antibodies
- antibodies
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε εξανθρωπισμένα αντισώματα κατά της ανθρώπινης GPVI και χρήσεις αυτών.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15179908 | 2015-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125400T1 true CY1125400T1 (el) | 2025-05-09 |
Family
ID=53836426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100511T CY1125400T1 (el) | 2015-08-05 | 2022-07-26 | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10842870B2 (el) |
| EP (2) | EP4091628A1 (el) |
| JP (2) | JP7076082B2 (el) |
| KR (1) | KR102751174B1 (el) |
| CN (2) | CN108289939B (el) |
| AU (1) | AU2016301969B2 (el) |
| BR (1) | BR112018002382A8 (el) |
| CA (1) | CA2994629A1 (el) |
| CY (1) | CY1125400T1 (el) |
| DK (1) | DK3331553T3 (el) |
| ES (1) | ES2923677T3 (el) |
| HR (1) | HRP20220910T1 (el) |
| HU (1) | HUE059655T2 (el) |
| IL (1) | IL257323B2 (el) |
| LT (1) | LT3331553T (el) |
| MX (1) | MX2018001465A (el) |
| PL (1) | PL3331553T3 (el) |
| PT (1) | PT3331553T (el) |
| RS (1) | RS63482B1 (el) |
| SI (1) | SI3331553T1 (el) |
| SM (1) | SMT202200317T1 (el) |
| WO (1) | WO2017021539A2 (el) |
| ZA (1) | ZA201800804B (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017021539A2 (en) | 2015-08-05 | 2017-02-09 | Acticor Biotech | Novel anti-human gpvi antibodies and uses thereof |
| TWI810173B (zh) * | 2017-02-03 | 2023-08-01 | 法商艾提寇生物技術公司 | 使用抗人類ｇｐｖｉ抗體抑制血小板凝集 |
| IL278323B2 (en) * | 2018-05-16 | 2025-05-01 | Morphosys Ag | Antibodies directed against glycoprotein IV |
| WO2021250026A1 (en) * | 2020-06-08 | 2021-12-16 | Acticor Biotech | Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome |
| CN118043349B (zh) * | 2021-06-11 | 2024-11-15 | 丰华生物有限公司 | 一种人源化抗人GPVI单克隆抗体Fab片段及其应用 |
| EP4399228A1 (en) | 2021-09-07 | 2024-07-17 | Etablissement Français du Sang | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering |
| US20250154252A1 (en) | 2022-02-21 | 2025-05-15 | Acticor Biotech | Treatment of cardiovascular diseases using anti-human gpvi antibodies |
| EP4431526A1 (en) | 2023-03-16 | 2024-09-18 | Emfret Analytics GmbH & Co. KG | Anti-gpvi antibodies and functional fragments thereof |
| EP4556492A1 (en) | 2023-11-14 | 2025-05-21 | Acticor Biotech | Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) * | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| WO2001016321A1 (en) * | 1999-09-01 | 2001-03-08 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1224942A1 (en) | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| EP1406929A2 (en) | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
| GB0130543D0 (en) | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| GB0511590D0 (en) | 2005-06-07 | 2005-07-13 | Procorde Gmbh | Anti-thrombotic agents |
| EP1538165A1 (en) | 2003-12-03 | 2005-06-08 | Procorde GmbH | Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4 |
| US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| CA2565063A1 (en) | 2004-04-29 | 2005-11-24 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein vi antibodies and method thereof |
| EP1876240B1 (en) | 2005-04-28 | 2012-08-22 | Mochida Pharmaceutical Co., Ltd. | Anti-human platelet membrane glycoprotein vi monoclonal antibody |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| EP1916259A1 (en) * | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| KR20120102125A (ko) * | 2009-12-18 | 2012-09-17 | 사노피 | Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도 |
| KR101767717B1 (ko) * | 2011-09-01 | 2017-08-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-인간 xcr1 항체 |
| WO2017021539A2 (en) | 2015-08-05 | 2017-02-09 | Acticor Biotech | Novel anti-human gpvi antibodies and uses thereof |
-
2016
- 2016-08-05 WO PCT/EP2016/068778 patent/WO2017021539A2/en not_active Ceased
- 2016-08-05 DK DK16750775.5T patent/DK3331553T3/da active
- 2016-08-05 PL PL16750775.5T patent/PL3331553T3/pl unknown
- 2016-08-05 CA CA2994629A patent/CA2994629A1/en active Pending
- 2016-08-05 BR BR112018002382A patent/BR112018002382A8/pt not_active Application Discontinuation
- 2016-08-05 SM SM20220317T patent/SMT202200317T1/it unknown
- 2016-08-05 HU HUE16750775A patent/HUE059655T2/hu unknown
- 2016-08-05 AU AU2016301969A patent/AU2016301969B2/en active Active
- 2016-08-05 SI SI201631573T patent/SI3331553T1/sl unknown
- 2016-08-05 EP EP22160888.8A patent/EP4091628A1/en not_active Withdrawn
- 2016-08-05 RS RS20220683A patent/RS63482B1/sr unknown
- 2016-08-05 IL IL257323A patent/IL257323B2/en unknown
- 2016-08-05 MX MX2018001465A patent/MX2018001465A/es unknown
- 2016-08-05 CN CN201680055046.0A patent/CN108289939B/zh active Active
- 2016-08-05 CN CN202210892269.XA patent/CN115925935A/zh active Pending
- 2016-08-05 KR KR1020187006083A patent/KR102751174B1/ko active Active
- 2016-08-05 PT PT167507755T patent/PT3331553T/pt unknown
- 2016-08-05 LT LTEPPCT/EP2016/068778T patent/LT3331553T/lt unknown
- 2016-08-05 JP JP2018506340A patent/JP7076082B2/ja active Active
- 2016-08-05 ES ES16750775T patent/ES2923677T3/es active Active
- 2016-08-05 US US15/750,082 patent/US10842870B2/en active Active
- 2016-08-05 HR HRP20220910TT patent/HRP20220910T1/hr unknown
- 2016-08-05 EP EP16750775.5A patent/EP3331553B1/en active Active
-
2018
- 2018-02-07 ZA ZA2018/00804A patent/ZA201800804B/en unknown
-
2020
- 2020-08-20 US US16/998,383 patent/US20200384106A1/en not_active Abandoned
-
2021
- 2021-07-15 JP JP2021116845A patent/JP7277689B2/ja active Active
-
2022
- 2022-07-26 CY CY20221100511T patent/CY1125400T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| CY1124993T1 (el) | Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20 | |
| CY1125241T1 (el) | Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους | |
| CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
| CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| CY1118168T1 (el) | Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| MX2022005202A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
| HUE066651T2 (hu) | CD3-t kötõ antitestek | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| BR112016022658A2 (pt) | anticorpos anti-ox40 e métodos de uso | |
| MX385456B (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| EA201992756A3 (ru) | Антитела против cd48 и их конъюгаты | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| IL262588A (en) | Humanized anti-basigin antibodies and the use thereof |